Current and emerging pharmacotherapies for primary CNS lymphoma.

Item

http://www.wikidata.org/entity/Q42126754

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Current and emerging pharmacotherapies for primary CNS lymphoma.

@en

Current and emerging pharmacotherapies for primary CNS lymphoma.

@nl

type

Item

label

Current and emerging pharmacotherapies for primary CNS lymphoma.

@en

Current and emerging pharmacotherapies for primary CNS lymphoma.

@nl

prefLabel

Current and emerging pharmacotherapies for primary CNS lymphoma.

@en

Current and emerging pharmacotherapies for primary CNS lymphoma.

@nl

P1476

Current and emerging pharmacotherapies for primary CNS lymphoma.

@en

P2093

Philip J Bierman

http://www.w3.org/2001/XMLSchema#string

Prathima Prodduturi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system

Pathway analysis of primary central nervous system lymphoma.

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Prospective trial on topotecan salvage therapy in primary CNS lymphoma.

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

P304

219-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S7752

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22654527

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

3362327

http://www.w3.org/2001/XMLSchema#string